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INTRODUCTION 
 
 
 Hepatitis B virus, Hepatitis C virus and Human Immuno 
Deficiency virus have in the recent years posed significant 
challenges to the health care system.  These viruses have a 
marked ability to spread from one person to another by 
parenteral route especially sexual contact.  Eventhough blood 
transfusion is the most effective method of transmission for 
all these viruses, introduction of stringent measures in the 
recent times have reduced this method of transmission to a 
considerable extent.  Concomitant infection of these viruses 
leads to higher frequency of carrier state and severe 
manifestations of the disease. 
 
 Whereas 40 million individuals are estimated to be 
infected with HIV worldwide, nearly 400 million people are 
chronic HBV carriers.  There is no doubt regarding the fact 
that HBV is more infectious than HIV.  Data from different 
regions in the world give highly variable prevalence rates for 
the co-infection of HBV and HCV in HIV patients.  Even 
reports published from various parts of India give different 
prevalence rates for these co-infections. 
 
 This depends a lot on geographical distribution of study 
as well as the group of people under study.  For example 
various reports from the state of Manipur and other north 
eastern states in India showed a high prevalence of HBV and 
HCV co-infection.  In many studies where the study 
population was mainly injection drug users a high prevalence 
of HBV and HCV is reported as in the case of North eastern 
States where IDU is the main mode of transmission (31,32)  .  
 
 Liver disease caused by chronic Hepatitis B virus 
infection is currently an important cause of morbidity and 
mortality among HIV infected patients in Western world, 
where classical complications of severe immunodeficiency 
have declined dramatically as a result of widespread use of 
potent anti retroviral therapies.  With the availability of these 
potent anti retroviral drugs in this part of world, the same 
scenario is bound to happen here also(1). 
 
 The presence of HIV infection increases the risk of 
chronicity after exposure to HBV.  Moreover it reduces the 
rate of spontaneous HBs Ag and HBeAg seroconversion.  The 
prevalence of HBeAg negative chronic hepatitis B, as well as 
the HBV inactive carrier state tend to be lower in HBV/HIV 
co-infected individuals.  Several clinical studies have shown 
that the risk of end stage liver disease is significantly 
increased in HIV infected patients with chronic Hepatitis B.   
 
 HIV infection appears to speed the rate of progression of 
chronic hepatitis C to end stage liver disease.  But this 
accelerated progression has not been observed in all studies(1).  
 
 The co-infection of HBV or HCV in HIV patients 
warrants special care while initiating anti retroviral therapy 
for HIV.  This prompts the physician to take decisions 
regarding the choice of drugs as well as treating those co-
infections whenever necessary. 
 
 Although the impact of HIV on HBV and HCV is 
established by many studies, it is not known whether HCV or 
HBV accelerate the progression of HIV(2,20).   
 
 In the light of above facts, the need for study regarding 
co-infection of Hepatitis B and Hepatitis C in HIV positive 
patients of Government General Hospital and Madras Medical 
College was felt and hence this study was undertaken. 
 REVIEW OF LITERATURE 
 
HISTORICAL ASPECTS 
AIDS was first recognised in 1981 in the United States.  
In 1983, human immuno deficiency virus was isolated.  In 
1984 it was established as the cause of AIDS.  In the year of 
1985, a sensitive enzyme linked immunosorbent assay was 
developed for the detection of HIV(35).  
 
In the case of Hepatitis B virus, in the year of 1969, 
Blumberg and co-workers reported a protein antigen in the 
serum of an Australian aborgine which gave a clearly defined 
line of precipitation with sera from two hemophiliacs, who had 
received multiple transfusions. This antigen was called 
Australia antigen.  In the year 1968, this antigen was shown 
to be associated with hepatitis and was subsequently shown 
to be the surface component of the hepatitis B virus.  The 
32nm particle which is the complete hepatitis B virus was 
first described by Dane and colleagues in 1970(37). 
 
Hepatitis C virus came to the light with experimental 
transmission of infection from cases of post transfusion 
hepatitis to Chimpanzees.  Till then this organism was 
grouped under non A non B (NANB) hepatitis agent (37). 
 
ETIOLOGICAL AGENTS 
 HIV- Acquired Immuno Deficiency Syndrome (AIDS) is 
caused by Human Immuno Deficiency Virus (HIV). It belongs 
to the family of retroviruses and sub family of lenti viruses.  
2 types of HIV are identified, HIV-1 and HIV-2.   HIV-1 is a 
more virulent pathogen than HIV-2.  HIV-1 virus is reported 
more in India.  This virus is found in all body fluids and 
organs.  But they are present in very large numbers in semen, 
vaginal & cervical secretions and blood.  The central nervous 
system, testis and lymph nodes act as reservoir of HIV.  But 
highest concentration of HIV among body fluids is found in 
cerebrospinal fluid.  HIV genome is 9.2 kbp in size (26). 
 
HBV:  Hepatitis B virus is a DNA virus belonging to the 
family hepadna virus and is classified as Hepadna virus  
type-I.  Hepatitis B isolates fall into atleast 8 sub types  and 7 
genotypes A-G.  Types A&D predominate in US and Europe,  
while B&C in Asia.  Genotype B is associated with less rapidly 
progressive liver disease.  HBV is also present in all 
secretions. HBV DNA codes for four sets of viral products.  
They are 's', 'c', 'p' and 'x'.  Envelope protein HBs Ag is the 
product of 's' gene of HBV.  Nucleocapsid proteins are coded 
for by the 'c' gene and antigen expressed on the surface of the 
nucleocapsid is referred to as Hepatitis B core antigen 
(HBcAg).  The corresponding antibody is anti HBc.  HBcAg 
remains in the hepatocyte and do not circulate in the serum.  
Third Hepatitis B virus antigen is Hepatitis B e 
antigen(HBeAg).  This denotes high level of replication and 
infectivity.  Antibody to HBeAg when it appears may be a 
harbinger of clinical improvement.  DNA polymerase directs 
replication and repair of HBV DNA.  The 'x' gene codes for 
HBxAg and it effects Calcium release.  Its genome size is 3.2 
kbp (34). 
 
HCV :  Hepatitis C before its identification was labelled 
as non A, non B hepatitis.  It is a linear single strand RNA 
virus.  HCV is the only member of hepaci virus in the family 
flavi-viridae.  The replication rate of HCV is very high 1012 
virions per day.  But its half life is 2.7 hours.  Atleast six 
distinct genotypes as well as sub types within genomes of 
HCV have been identified by nucleotide sequencing.  The 
genotypic and quasi-species diversity of HCV, resulting from 
its high mutation rate interferes with effective humoral 
immunity.  Though neutralising antibodies to HCV have been 
demonstrated they tend to be short lived.  Its genome size is 
9.5 kbp (34,4). 
 
MODES OF TRANSMISSION 
 All three viruses spread mainly through parenteral 
route. 
TABLE-1:   Characteristics of HIV transmission 
S.No. Modes of Transmission Efficacy Source of Infection 
1 Sexual intercourse,  homosexual, heterosexual 0.1 to 1.01 80-85% 
2 Blood transfusion 90 to 95% 3-5% 
3 Perinatal 20 to 40% 2-3% 
4 Injection drug user 0.5 to 1% 3-5% 
5 Needle stick exposure <0.1% - 
(26) 
 Regarding sexual intercourse, the receiving partner is at 
a greater risk than the insertive partner.  Anal sex carries a 
higher risk than vaginal sex. 
 
 In the case of perinatal / ante natal transmission, the 
risk is about 23-30% before birth, 50-65% during birth and 
12-20% via breast feeding. 
 
HBV :  Transmission is mainly by percutaneous route.  This 
virus is highly infectious and very minute amounts of some 
carrier sera as little as 0.000001 ml can transmit the disease.  
Therapeutic and diagnostic procedures, tattooing, 
accupuncture, ritual circumcision, nose and ear piercing, 
sharing of razors and needles, sexual intercourse and kissing 
apart from blood transfusion can spread the virus.  Perinatal 
transmission from mother to child is another important mode 
of transmission.  But patients infected through male 
homosexual contact tend to show the highest rates of 
transmission along with injection drug users(38). 
 
HCV:  Hepatic C virus was mainly transmitted through blood 
transfusion of contaminated blood and blood products until a 
few years ago.  But with the stringent screening measures 
taken this has come down to a great extent.  This virus is now 
transmitted through other means like sharing of needles in 
injection drug users, tattoing and scarification and traditional 
circumcision with contaminated instruments.  The risk of 
sexual and perinatal transmission is small (38). 
EPIDEMIOLOGY 
 HIV infection is a global pandemic with an estimated 
population of ~37 million world wide, two thirds of whom are 
in subsaharan Africa.  An estimated 2.5 millon children below 
the age of 15 are living with HIV/AIDS.  Now it is the fourth 
leading cause of mortality. 
 
INDIA HIV estimates in India is close to 5.3 million in the 
age group of 15-49 years.  Almost 89% cases are in the age 
group of 15-44 years.  Of these 73% are men and 27% are 
women.  Its prevalance varies from State to State. 
 
States are classified into 3 groups 
Group-I  High prevalence states:  States with 1% or more of 
ante natal women, like Maharashtra, Karnataka, 
Andhrapradesh, Manipur, Mizoram, Dadar and Nager Haveli. 
Tamil Nadu was previouly in this group, but of late antenatal 
case prevalence dropped to 0.63 in 2004. 
 
Group-II:  In these states HIV infection has crossed 5% or 
more among high risk groups but less than 1% in antenatal 
women.   
 Eg: Gujarat, Rajasthan, Kerala & Goa. 
 Group-III :  Remaining states are with <5% prevalences in 
high risk groups and <1% in ANC (26). 
 
HBV :  It is estimated that there are around 400 million 
chronic HBV carriers.  Infection with HBV is a major cause of 
morbidity and mortality is SEAR, were more than one third of 
population is estimated to be infected with HBV.  In western 
countries the prevalence of chronic HBV infection is overall 10 
fold higher among HIV positive individuals than general 
population.  Serological evidence of previous exposure to HBV 
is found in more than 80% of HIV +ve patients(2). 
 
 Based on the different HBsAg carrier rates, countries in 
the South east asian region/South asian region can be 
classified into 3 epidemiological patterns. 
 
Type-I Carrier rate 0.9-1% --> Nepal and Sri Lanka 
Type-II Bhutan, India, Indonesia, Maldives — carrier rate 
  5-7%. 
 
  In India alone an estimated 43-45 million HBsAg  
  carriers are present. 
Type-III The carrier rate is 9-12% . 
Countries like Myanmar, Thailand, Bangladesh, 
Korea included in this group (38). 
 
Hepatitis 'C':  WHO estimates that 3% of world population is 
infected with HCV and around 170 million individuals are 
chronic carriers at risk of developing liver cirrhosis and liver 
cancer.  Numerous studies have documented a high rate of 
HCV co-infection among HIV infected injection drug users and 
persons with hemophilia.  In India it is estimated that 2% of 
general population is infected with HCV (38). 
 
Pathogenesis 
HIV/AIDS:    The natural history of HIV infection begins as 
soon as the virus enters the body of a susceptible host.  HIV 
predominently infects the helper CD4 lymphocytes.  As the 
numbers and function of CD4 cells decline immune deficiency 
sets in and this will in turn lead to opportunistic infections 
and maligancies.  By this time CD4 counts fall below a critical 
level below 200 cells/µl and reach the stage of advanced HIV 
disease.  Dissemination of virus to lymphoid organs is a major 
factor in the establishment of chronic and persistent 
infection.  Despite the robust cellular and humoral immune 
response against the primary infection, the virus succeeds in 
escaping the immune mediated clearance and is virtually 
never eliminated completely from the body in all HIV infected 
individuals.  There exists a pool of latently infecting resting 
CD4 T Cells that serve as one of the persistent reservoirs of 
viruses.  One other striking feature of HIV infection is that, 
clinical latency is not accompanied by microbiologic latency 
as some degree of virus replication invariably occurs (35). 
 
Hepatitis B:      The existence of inactive hepatitis B carriers 
with normal liver histology and function suggests that the 
virus is not directly cytopatic.  Patients with defects in cellular 
immune competence are more likely to remain chronically 
infected rather than to clear virus is cited to support the role 
of cellular immune responses in the pathogenesis of 
Hepatitis-B related liver injury.  Although the precise 
mechanisms of liver injury in HBV infection remains elusive, 
studies of nucleocapsid protiens have revealed profound 
immunological tolerance to HBV,  in babies born to mothers 
with highly replicative chronic HBV infection (34). 
 
Hepatitis C: Cell mediated immune responses and 
elaboration by T cells, of antiviral cytokines contribute to 
containment of infection and pathogenesis of liver injury by 
Hepatitis C.  HCV infection of lymphoid cells may play a role 
in moderating immune responsiveness to the virus.  The role 
of virus activated CD4 helper T cells that stimulate, via the 
cytokines they elaborate, HCV specific CD8 cytotoxic T cells is 
supported by many studies.  Cross reactivity between viral 
and host auto antigens has been invoked to explain the 
association between Hepatitis C and a subset of patients with 
autoimmune hepatitis and antibodies to liver kidney 
microsomal antigen (LKM) (34). 
 
HIV/Hepatitis B Co-infection: The risk of HBV associated 
end stage liver disease, seems to be increased in the setting of 
HIV co-infection.  The presence of HIV infection increases the 
risk of chronicity after exposure to HBV.  It reduces the rate of 
spontaneous HBsAg and HBeAg sero conversion.  Thus the 
prevalence of HBeAg negative chronic hepatitis B as well as 
the HBV inactive carrier state tends to be lower. 
 
 Despite a higher serum HBV-DNA level seen in HIV 
patients, hepatic necro inflammation tends to be milder in 
HIV/HBV co-infected individuals.  However the enhanced 
replication levels of HBV in HIV co-infected patients may 
result paradoxically in the progression of more severe liver 
fibrosis (1). 
 
HIV/Hepatitis C Co-infection:  HIV-I infection appears to 
speed the progression of chronic hepatitis C to end stage liver 
disease to as little as 10 years after exposure.  The average 
risk of progressive liver disease is 2.9 times higher among 
HCV/HIV-1 co-infected persons than among persons infected 
only with HCV.  Evaluation of liver histology indicates the 
presence of more extensive fibrosis as well as a greater rate of 
fibrosis progression among HCV/HIV-1 co-infected than 
among those with HCV infection alone (2). 
 
Clinical manifestations: 
HIV:   After entry of HIV, the HIV replication will be going on 
in the body.  Antibodies useful in detection of HIV will be in 
low titres and will not be detectable during this period.  
However the patient will be in a carrier state capable of 
transmitting the disease.  This stage lasts for 6 weeks – 12 
weeks.  This phase is known as window period. 
 
Acute HIV Syndrome: It is estimated that 50-70% 
people with HIV infection experience an acute clinical 
syndrome approximately 3-6 weeks after primary infection.  
The typical clinical features occur along with a burst of 
plasma viremia.  Symptoms usually persist for one to several 
weeks.  The clinical findings include fever, pharyngitis, 
lymphadenopathy, head ache, retro orbital pain, arthralgia, 
myalgia, lethargy, malaise, anorexia, weight loss, nausea, 
vomiting and diarrhoea.  Neurological manifestations may 
include meningitis, encephalitis, peripheral neuropathy and 
myelopathy.   Dermatological manifestations include 
mucocutaneous ulcerations and erythematous maculopapular 
rash. 
 
Asymptomatic stage:  Following acute HIV syndrome the 
patient may enter a stage of clinical latency i.e., the 
asymptomatic stage.  HIV disease with active virus replication 
is ongoing and progressive during this phase.  The average 
rate of CD4 cell decline is 50 cells/µl/year.  When the CD4 
cell count is less than 200/µl the resulting state of 
immunodeficiency puts the patient at a high risk for 
opportunistic infections and neoplasms. 
 
Persistent generalised lymphadenopathy:  This is indicated 
by the presence of enlarged lymph nodes more than 1 cm in 
length in two or more extra inguinal sites for more than 3 
months without any obvious cause.  It is actually an 
immunological response by the reticuloendothelial system to 
HIV infection with an attempt to arrest the virus in the lymph 
nodes. 
 
Symptomatic Disease:   Diagnosis of AIDS is made in any 
one with HIV infection and CD4 count <200/µl and in any one 
with HIV infection who develops one of the HIV associated 
diseases considered to be indicative of severe defect in cell 
mediated immunity. 
 
1993 revised classification system for HIV infection 
and expanded AIDS surveillance case definition for 
adolescents and adults. 
Table-II 
CD4 
categories 
Asymptomatic 
Acute 
HIV/PGL 
Symptomatic 
but not A or C 
AIDS 
indicator 
condition 
>500/µl A1 B1 C1 
200-499/µl A2 B2 C2 
<200/µl A3 B3 C3 
 
Clinical Categories 
Category-A :   One or more conditions of the following in an 
HIV +ve who is more than 13 years of age  
(1) Asymptomatic HIV infection 
(2) Persistent generalised lymphadenopathy 
(3) Acute HIV infection 
with accompanying illness or history of acute HIV 
infection. 
 
Category-B :   Symptomatic conditions not included in 
clinical category C and that meet atleast one of the following. 
(1) The conditions are attributed to HIV infection or are 
indicative of defect in cell mediated immunity. 
(2) The conditions are considered to have a clinical course 
or require management that is complicated by HIV 
infection. 
Eg: ¾ Bacillary angiomatosis 
 ¾ Oropharyngeal & Vulvo vaginal candidiasis 
 ¾ Cervical dysplasia (moderate or severe) / 
  Cervical carcinoma insitu 
 
 ¾ Constitutional symptoms like fever ≥38.5ºC or 
  Diarrhoea for more than one month. 
  ¾ Oral hairy leukoplakia 
 
¾ Herpes Zoster which is either multidermatomal or 
atleast two distinct episodes. 
 
¾ Idiopathic thrombocytopenic purpura 
 
¾ Listeriosis 
 
¾ Pelvic inflammatory disease, particularly if 
complicated  by tubo ovarian abscess. 
 
¾ Peripheral neuropathy. 
 
 
Category-C :   AIDS defining illness 
 ¾ Candidiasis of trachea, bronchi or lungs. 
 
 ¾ Esophageal candidiasis 
 
 ¾ Invasive cervical cancer 
 
¾ Coccidioidomycosis (disseminated or extra 
pulmonary) 
 
¾ Cryptococcosis (extra pulmonary) 
 
¾ Cryptosporidiosis (chronic intestinal > 1 month) 
 
¾ Cytomegalo virus disease (other than spleen, liver 
or nodes) 
 
¾ CMV retinitis (with loss of vision) 
 
¾ HIV related encephalopathy 
 
¾ Herpes simplex : chronic ulcers > 1 month or 
bronchitis, pneumonia or esophagitis 
 
¾ Histoplasmosis :  Disseminated or extrapulmonary 
 
¾ Isosporiasis (chronic intestinal > 1 month) 
 
¾ Kaposi's sarcoma 
 
¾ Burkitt's lymphoma & primary CNS lymphoma 
 
¾ Mycobacterium Avium complex or Mycobacterium 
Kansasii – Disseminated or extra pulmonary  
 
¾ Mycobacterium, other species or unidentified 
species (disseminated or extra pulmonary) 
 
¾ Pneumocystis carinii pneumonia 
 
¾ Recurrent pneumonia 
 
¾ Progressive multifocal leuko encephalopathy 
 
¾ Salmonella septicemia 
 
¾ Toxoplasmosis of brain  
 
 ¾ Wasting syndrome due to HIV  (26, 35) 
 
 
 
 
 Hepatitis B and Hepatitis C 
Acute Viral Hepatitis:     Usaually the incubation period of 
Hepatitis-B extends from 30-180 days and Hepatitis-C,  
15-160 days.  In the case of HBV, the onset can be acute or 
insidious and for Hepatitis-C it is usually insidious.  
Prodromal symptoms of acute viral hepatitis are systemic and 
quite variable.  Constitutional symptoms are anorexia, 
nausea, vomiting, fatigue, malaise, arthralgias, myalgias, 
head ache, photophobia, pharyngitis and coryza which may 
precede the onset of jaundice by 1 to 2 weeks.  Patients are 
usually afebrile unless in the case of Hepatitis-B, if heralded 
by serum sickness like syndrome.  Then there is the phase of 
clinical jaundice which is followed by recovery. 
Extra Hepatic manifestations : Serum sickness like 
syndrome can complicate acute hepatitis due to Hepatitis-B.  
In chronic hepatitis B glomerulonephritis with nephritic 
syndrome is occasionally observed.  Poly arteritis nodosa 
develops in considerably fewer than 1% patients with chronic 
HBV infection, but 20-30% with PAN have HBsAg in serum.  A 
substantial proportion of essential mixed cryoglobulinemia 
cases is associated with hepatitis C virus infection.  This is 
less common with hepatitis B.  Immune complex glomerulo 
nephritis is another recognised extra hepatic manifestation of 
chronic hepatitis C infection.  
 
Co-infection with HIV increases chronicity of infection 
for both Hepatitis B and Hepatitis C.  Unusual histologic 
pattern of fibrosing cholestatic hepatitis may occur in patients 
with severe immuno suppression with concomitant HBV 
infection. 
 
DIAGNOSIS :   
HIV:  HIV infection is diagnosed by detecting antibodies or / 
and antigens in the body. 
 
HIV Antibody Tests: 
1. ELISA tests: It is a standard screening test for HIV 
infection (enzyme immuno assay).  This solid phase 
assay is an extremely good screening test with a 
sensitivity more than 99.5%. 
 
2. Rapid Test:  It is a quick test and results 
could be obtained in 30 minutes. 
 
3. Western Blot Test: It is a confirmatory test and is 
more specific.  Confirmation can also be done by using 
results from two or three consecutive different 
ELISA/Rapid test kits. 
 
HIV Antigen Tests: 
1. RT-PCR for viral RNA 
2. b-DNA test (branch-b) 
 The above PCR (polymerase Chain Reaction) tests 
become positive after 72 hours of infection. 
 
 Viral load assessment tests like NASBA become positive 
after 72 hours of infection. 
 
 P24 antigen becomes positive after 2 weeks of infection. 
 HIV Testing Strategies: WHO/GOI have developed these 
strategies. 
 
Strategy-I: Used  for ensuring donation safety by using 
ELISA/RAPID/Simple tests for HIV once.  If results are 
negative, serum is considered free of HIV.  If serum is positive, 
the unit of blood is discarded and donor sent for VCTC.  This 
strategy is used in blood banks . 
 
Strategy-II : Used for surveillance and for diagnosis of 
HIV infection only if some AIDS indicator disease is present.  
If the first ELISA is negative, the serum sample is considered 
negative.  If the first ELISA is positive, the serm is subjected 
to a second ELISA.  If the second confirms the report of the 
first, the serum sample is considered positive. 
 
Strategy-III : It is used to diagnose HIV infection in 
asymptomatic individuals indulged in high risk behaviour.  It 
is similar to strategy II, but with an added confirmation of a 
third reactive ELISA test, for a positive reported sample by the 
two previous ELISAs. 
 Supplementary/Confirmatory tests are used in problem 
cases, eg: in cases of indeterminate / discordant results 
E/R/S. (26, 35, 1). 
 
HBV : A diagnosis of HBV infection in the setting of acute 
Hepatitis-B is made by detection of HBsAg in serum.  
Sometimes it may be low but diagnosis can be established 
with the help of IgM anti HBc. 
Commonly Encountered Scrologic Patterns of Hepatitis B Infection: 
Table-III 
 
S.
No
. 
HB
sA
g 
An
tiH
bs
 
An
ti H
Bc
 
HB
eA
g 
An
tiH
Be
 
Interpretation 
1 + - IgM + - Acute hepatitis B with infectivity 
2 + - IgG + - Chronic hepatitis B high infectivity 
3 + - IgG - + 
1. Late acute / chronic    hepatitis B 
2. HBeAg negative precore mutant 
Hepatitis B chronic or rarely acute 
4 + + + +/- +/1 
1. HBsAg of one sub type and hetero 
typic anti-HBs. 
2. Process of seroconversion from 
HBsAg to anti HBs 
5 - - IgM +/- +/- 
1. Acute hepatitis B 
2. Anti HBc "window" 
6 - - IgG - +/- 1. Low level hepatitis B carries 2. Hepatitis B in remote part 
7 - + IgG - +/- Recovery from hepatitis 
8 - + - - - 
Immunisation (after vaccination) 
Hepatitis B in the remote past , 
false positive 
- HBV DNA by PCR:   This test can detect as few as 100 or 
1000 virions / ml.   
 
The persistance of HBeAg beyond 3 months or HBsAg 
beyond 6 months after acute hepatitis signifies establishment 
of chronic hepatitis. 
 
Hepatitis-C :  Specific diagnosis is possible by 
demonstrating presence of anti HCV in serum by 2nd or 3rd 
generation assays that detect antibodies to non structural or 
nucleocapsid proteins in upto 90-95% cases of acute 
Hepatitis-C and is >95% cases with chronic hepatitis C.  A 
recombinent immunoblot assay can be used to establish viral 
proteins (RIBA).  Assay for HCV RNA are the most sensitive 
tests for HIV infection and represent the "gold standard" in 
establishing the diagnosis. 
 
Hepatitis 'C' RNA : Three diagnostic assays have been 
approved for qualitative detection of HCV RNA. Two of the 
assays use RT-PCR and have a lower limit of detection of 50-
100 IU/µl.  3rd one uses transcription mediated amplification 
and has a lower limit of detection of 10 IU/µl.  Quantitative 
tests for HCV RNA include quantitative RT-PCR or branched 
DNA signal amplification assays (1). 
 
In HBV/HIV Co-infection: Isolated anti-hepatitis B core 
antigen is frequently recognised, particularly among patients 
with more severe immuno deficiency (2). 
 
Treatment :  HIV/AIDS -  These include psychosocial 
support, ongoing counselling, patient education, prevention of 
transmission, prevention and treatment of opportunistic 
infections and anti retroviral therapy. 
 
Anti – retroviral therapy : 
Aims : 
1. To prolong life and improve quality of life. 
2. Reduction of viral replication as much as possible to 
halt disease progression and to prevent and reduce drug 
resistant variants. 
3. To achieve immune reconstitution and thus to prevent 
opportunistic infections and malignancies . 
4. To achieve reduction in HIV transmission. 
 
DRUGS: 
 Nucleoside reverse transcriptase inhibitors 
 Non nucleoside reverse transcriptase inhibitors 
 Protease inhibitors – Most potent drugs. 
 Fusion / Entry inhibitors – Inhibit HIV fusion with CD4 
membrane. 
Antiretroviral Drugs 
Table-IV 
NRTI NNRTI PI Fusion Inhibitors 
- Zidovudine - Delavirdine - Indinavir Enfuvirtide 
- Didanosine - Nevirapine  - Ritonavir  
- Stavudine - Efaviren z - Nelfinavir  
- Lamivudine  - Lopinavir  
- Zalcitabine  - Saquinavir  
- Abacavir  - Amprenavir  
 
Recommended Regimens: 
1. 2 NRTIs + 1 NNRTI 
2. 2 NRTIs + 1 PI 
3. 3 NRTIs 
4. 2 NRTIs + P1 Boosting (2 PIs) 
 
Guidelines for starting ART 
Table-V 
Category CD4 count/µl Recommendation 
Symptomatic HIV any value treat 
Asymptomatic HIV <200 treat 
Asymptomatic HIV >200 Consider treatment based 
on CD4 count, Rate of 
CD4 decline, Viral load 
>50,000 to 1,00,000 
copies. 
Take into consideration 
- Adherence issues 
- Potential drug interation 
- Risk for adverse effects. 
 
Hepatitis B & Hepatitis C : 
— Acute Hepatitis B ¾ Because 99% of patients 
spontaneously recover no 
treatment is usually required. 
— Acute Hepatitis C ¾ As it is sure that the condition 
progresses to chronic form in 
most of the patient's treatment is 
mandatory, preferably with long 
acting pegylated interferon + 
nucleoside analogue ribavirin. 
 
Chronic Hepatitis B  :  Interferon α was the first approved 
drug for therapy.  Other drugs useful are lamivudine, Adefovir 
and Tenofovir which are primarily used against HIV infection.  
Other drug is emtricitabine.  Entecavir and telbivudine can 
reduce HBV DNA levels and are useful in treatment. 
 
Patients who are candidates for antiviral therapy in 
chronic Hepatitis B. (34). 
 
Table-VI 
 
S.No. Clinical features 
In
te
rf
er
on
 
La
m
iv
u
di
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e 
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r 
1 Detectable markers HBV replication Yes Yes Yes 
2 Normal ALT activity No No No 
3 ALT < 2 x upper limit of Normal No No No 
4 ALT > 2 x upper limit of Normal Yes Yes Yes 
5 Immuno competent Yes Yes Yes 
6 Immuno compromised No Yes Yes 
7 Adult acquisitional Yes Yes Yes 
8 Childhood acquisition No Yes Yes 
9 Compensated liver disease Yes Yes Yes 
10 Decompensated liver disease No Yes Yes 
11 HBeAg reactive Yes Yes Yes 
12 HBeAg(-) chronic Hepatitis Yes Yes Yes 
13 Interferon refractory No Yes Yes 
     (34). 
 
For chronic hepatitis C treatment is with ribavirin and 
pegylated interferon. 
 
HBV/HIV Co-infection: 
For hepatitis B treatment is indicated in presence of HIV in 
the following scenarios. 
1.  For active HBV replication. 
2.  HBeAg positive / HBV DNA > 105 copies / ml. 
3.  2 x upper limit of Alanine Aminotransferase. 
 
Scenario-1 : Indications are there to begin treatment for HIV 
but not for HBV. 
1. Consider withholding Tenofovir / Emtricitabine / 
Lamivudine for future use. 
2. Avoid using Lamivudine or Tenofovir as a single drug 
with anti HBV activity. 
 
Scenario-2 : When indications are present there for initiating 
treatment for HBV but not for HIV.  Use 
interferon (pegylated) or Adefovir.  Do not use 
Lamivudine / Emtricitabine / Tenofovir. 
 
Scenario-3: When indications are there to begin therapy 
against both HIV & HBV. 
¾ Lamivudine / Emtricitabine + Tenofovir.  Here two drugs 
with action against both HIV & HBV, these viruses are 
initiated with a third agent Efavirenz (1). 
HIV/HCV Co-infection : Persons susceptible to Hepatitis A 
virus infection should get vaccination against HAV (2 doses) 
because of increased risk of fulminant hepatic failure in these 
patients. 
 All patients with evidence of chronic hepatitis C in the 
form of who have detectable HCV RNA levels on qualitative 
assay, persistently elevated ALT levels > 2 times upper limit of 
normal and liver biopsy suggestive of portal or bridging 
fibrosis and moderate inflammation should receive treatment 
with pegylated interferon and Ribavirin apart from ART (1). 
Prevention: Vaccine is available only against hepatitis B but 
not against Hepatitis C or HIV. Practising safe sex, 
maintaining universal precautions while handling infective 
material practising post exposure prophylaxis in case of 
accidental exposure to infective materials are important.  
Mother to child transmission is reduced by Nevirapine / 
Zidovudine prophylaxis. 
 
AIMS AND OBJECTIVES 
1. To find out the prevalence of Hepatitis B virus and / or 
hepatitis C virus co-infection in HIV patients of 
Government General Hospital and Madras Medical 
College, Chennai. 
2. To find out the main modes of transmission / 
acquisition for HIV, HBV & HCV infections in the same 
population. 
3. To know the impact of co-infection on liver function. 
4. To determine the impact of HBV/HCV co-infection on 
HIV disease progression and vice versa. 
 
MATERIALS AND METHODS 
 
 The study was carried out at Government General 
Hospital and Madras Medical College, Chennai.  This study 
was made possible with the help of anti-retroviral treatment 
centre, Voluntary Counselling and Testing Centre, 
Department of Microbiology, Institute of Sexually Transmitted 
Diseases, Barnard Institute of Radiology and Central 
Research Unit of Government General Hospital & Madras 
Medical College. 
 
 A simple observational study (prevalance study; cross 
sectional study) was carried out over a period of one year from 
June,2005 to June, 2006.  Altogether one hundred HIV 
positive patients visiting GGH were selected for the study.  
Sampling was done by simple random sampling.  Informed 
consent was taken before testing of HIV at VCTC, Governent 
General Hospital and Madras Medical College. 
 
Inclusion Criteria: HIV positive individuals. 
 
Exclusion Criteria : 
¾ All HIV negative persons 
¾ Persons in the paediatric age group 
¾ Persons in the geriatric age group 
¾ Ante natal women 
¾ Those who are already on anti retroviral therapy. 
¾ Those who are known to be cases of alcoholic 
decompensated liver disease. 
¾ Those who present with altered level of sensorium or 
decreased level of consciousness. 
¾ More than one member from the same family. 
 
Parameters considered for analysis: 
1. Age,  2. Sex,   3. Educational Status,  4. Marital Status 
5. HIV – Serology status of spouse / partner 
6. Probable route of transmission of HIV divided under the 
following categories. 
 a) Sexual Æ Hetero / Homosexual 
    Æ Contact with commercial sex 
     worker 
 
    Æ Multiple sex partners 
 
 b) Injection drug user. 
 
 c) Blood transfusion 
 
 d) Iatrogenic 
  
 e) Unknown 
 
7. History of regular alcohol intake. 
8. CD4 count. 
9. WHO staging  
 i) Weight loss — a) +/-      b) if + > 10% / <10% 
 ii) Activity Æ number of days inactive the previous 
month 
 iii) Persistent generalised lymphadenopathy 
 iv) Acute HIV syndrome. 
 v) Oral candidiasis 
 vi) AIDS defining illness 
 
10. Liver Function Tests — including  
 a) Serum Bilirubin (SBb) 
 b) Alanine Aminotransferase (ALT, SGPT) 
 c) Aspartate amino transferase (AST/SGOT) 
 d) Alkaline Phosphatase (ALP) 
 e) Gamma Glutamyl Transpeptidase (GGT) 
 
11. Ultra Sonography of abdomen 
 a) Liver : Size & echoes 
 b) Portal vein – size 
 c) Spleen – size & splenic vein 
 d) Ascites 
 e) Venous Collaterals 
 
WHO – Clinical Groups: 
1. Clinical Group-I 
 Æ Acute HIV infection, persistent generalised 
lymphadenopathy. 
 Æ Asymptomatic normal activity. 
2. Clinical Group-II  (early stage disease) 
  
 Æ Weight loss, but less than 10% 
 Æ Mucocutaneous problems. 
 Æ Herpes Zoster 
 Æ Recurrent upper respiratory tract infection. 
 Æ Normal Actvity 
3. Clinical Group-III (intermediate Stage Disease) 
 Æ Weight loss more than 10% 
 Æ Chronic diarrhoea (>1 month) 
 Æ Prolonged fever (>1 month) 
 Æ Oral candidiasis 
 Æ Oral hairy leukoplakia 
 Æ pulmonary tuberculosis 
 Æ severe bacterial infection 
 Æ Bed ridden but less than 50% of day the previous 
month.  
 
 
4. Clinical Group-IV  (late stage disease) 
 Æ Definitive or presumptive diagnosis of any AIDS 
defining disease. 
 Æ Bed ridden for more than 50% of day the previous 
month. 
 (26). 
 Patients were tested for HIV by ELISA at VCTC after 
counselling and getting informed consent.  Positive results 
were confirmed by following strategy-II recommended by WHO 
/ GOI.  ELISA was done with kit Microlisa using 96 plate titer 
well. 
 
 CD4 count was estimated by facs count.  For this 2 ml 
of venous blood was collected into EDTA containing 
vacutainers. 
 
 About 5 ml of venous blood was collected from each 
patient and transferred into test tubes.  These test tubes were 
centrifuged at a speed of 4000 rotations per minute in an 
electric centrifuge for 5 minutes and serum was separated. 
 
 For HBsAg rapid test card from Intec products (XIAMEN) 
was used first and followed it up with microwell ELISA test 
(HEDALISA). 
 
 Fo anti-HCV Biozyme one step anti HCV test, with a 
sensitivity of 99% and specificity of 97-99% was used. 
 
 Serum Bilirubin was estimated by Jendrassik method.  
For alanine aminotransferase and Aspartate aminotransferase 
kit from "autopak" was used.  For GGT and alkaline 
phosphatase also kits from "autopak" was used and analysed 
with ERBA-CHEM-5plus semi-auto analyser. 
 
Following are the normal ranges for these tests. 
1. SGOT (AST) - 11-47 IU/ml 
2. SGPT (ALT) - 7-53 IU/ml 
3. GGT  Males : 11-50 IU/ml 
    Females : 7-32 IU/ml  
4. Alkaline Phosphatase : 38 – 126 IU/ml 
 
 For all the tests manufacturer's instructons were 
strictlty followed. 
 
 Ultra sound abdomen was done at BIR, GGH.  Following 
parameters were looked at. 
Liver :  Size & Echoes: 
 Size in mid clavicular line 
 Normal 1. < 13 cm (cranio-caudal) 
      2. < 15 cm (depending on body habitus)  
 Marginal Angle 
       <30º (left hepatic lobe, lateral) 
       < 45º (right hepatic lobe, caudal)  
 
Portal Vein : Luminal Width 
    <1.3 cm Æ normal 
    >1.5 cm Æ portal hypertension 
 
Spleen :   Maximum size  
    <11.0 cm (length) 
    <7.0 cm (width) 
<4.0 cm (depth, measured between splenic 
hilum and surface. 
Splenic Vein : <1.0 cm – Normal 
    >1.2 cm – portal hypertension  
  
Presence of Ascites / Venous collaterals : 
 Ultra sound scan was performed with ALOKA B mode 
Ultra sound scanner.  
 
 Statistical Analysis  was done with SPSS V6.  The 
characteristics of HIV positive patients with hepatitis co-
infection and those without co-infection were compared.  With 
categorical variables the chi-square test was applied.  To find 
out the association between liver enzymes with other variables 
like alcoholism, co-infection, CD4 count logistic regression 
was used.    
RESULTS 
 
Table-VII 
Age and Gender wise distribution of study population 
Age Male Female Total 
<30 19 10 29% 
31-40 46 11 57% 
>40 10 4 14% 
TOTAL 75 25 100% 
 
 The youngest in the study population was 23 years of 
age and oldest was 54 years of age.  The mean age of the 
study population was 34.79.  Highest number of individuals 
belonged to 31-40 years of age group followed by ≤ 30 years 
age group. 
 There were 75 males and 25 females in the study 
population. 
 
Table-VIII 
Educational/Literacy Status of study population 
Educational Qualification Frequency Percentage 
Illiterate 2 2% 
Lower primary school Education 15 15% 
Upper primary school Education 23 23% 
High School Education 41 41% 
Higher Secondary School 6 6% 
Above Higher Secondary School 13 13% 
TOTAL 100 100% 
 
 Among the study population there were only 2 
illeterates. 
Table-IX 
Marital Status of Study population 
 
Marital Status  Men Women 
Married 57 25 
Unmarried 18 0 
 
Out of the 75 males, 57 were married and 18 were unmarried.  
But all the 25 women in the study were married. 
 
 
 
 
Table-X 
HIV Status of Spouse / Partner  
 
HIV Status of spouse / partner Married 
Men 
Married 
Women 
Positive 19 24 
Negative 33 1 
Not known 5 0 
 
Thus out of 25 females, 24 had their husbands tested as 
positive for HIV.  But of 57 males, 19 of them had their wives 
tested positive for HIV.  There were 33 men with their wives' 
HIV status as negative and 5 of them don't know the HIV 
status of their wives. 
 
 
 
 
 
Table-XI 
Distribution of Study Population by CD4 count  
CD4 count Frequency Percentage 
≥ 500 3 3 
200 – 499 33 33 
50 – 199 52 52 
<50 12 12 
TOTAL 100 100 
 
 Thus the majority of individuals i.e. 52 of them had their 
CD4 count between 50-199/µl and 12 below 50 / µl.  There 
were 3 individuals with their CD4 counts above 500/µl and 
33 people with CD4 counts in between 200-499. 
 
 
Table-XII 
Distribution of Study Population by WHO Staging 
WHO Stage (Clinical) Frequency Percentage 
I 17 17 
II 33 33 
III 41 41 
IV 9 9 
TOTAL 100 100 
 
 There were 9 people belonging to clinical stage IV, but 
the maximum number of individuals i.e.41 individuals 
belonged to clinical Stage-III.  There were 17 people in Stage-I 
and 33 in clinical Stage-II. 
 
 
 
Table-XIII 
 
Distribution of Study Population by modes of transmission / acquisition 
 
Mode of Transmission Frequency of HIV +ve 
Hetero sexual 93 
Homo sexual 0 
Injection Drug user 5 
Blood/Blood related 
products 
1 
Iatrogenic 0 
Not known 1 
TOTAL 100 
 
 Majority in the study population, 93 of them had HIV 
through the hetero sexual mode.  All the men who were tested 
HIV positive in this group had history of sexual contact with 
commercial sex workers.  All the 24 women who were tested 
positive for HIV in this group had their husbands already 
tested positive for HIV.  There were no homosexuals in the 
study population.  The next highest share is by injection drug 
users, all males.  One person got the infection through 
probably, blood transfusion.  One person was not sure of the 
mode of acquisition. 
93
5 1 1 0 0
0
20
40
60
80
100
Hetero sexual Injection Drug
user
Blood/Blood
related
products
Not known Homo sexual Iatrogenic
MODES OF ACQUISITION OF HIV IN 
THE STUDY POPULATION
Series1
 
Table-XIV 
 
Hepatitis-B surface antigen and Anti HCV prevalence in study population 
 
Serum Positive Number examined Percentage 
HBsAg 8 100 8% 
Anti HCV 4 100 4% 
HBsAg and Anti HCV 1 100 1% 
 
 So, out of 100 persons, 8 tested positive for HBsAg and 
4 tested positive for anti HCV.  Out of the 100 persons only 
one had evidence of positivity for both HBsAg and anti HCV. 
 
 
Table-XV 
Age related prevalence of HBV / HCV 
 
Age 
group 
Total 
examined HBsAg+ 
Anti 
HCV+ 
Both 
HBsAg+ 
Anti 
HCV+ 
% 
HBsAg+ 
%Anti 
HCV+ 
Both 
HBsAg+ 
Anti 
HCV+ 
≤30 29 4 1 1 13.8% 3.4% 3.4% 
31-40 57 4 3 - 7% 5.26% - 
>40 14 - - - - - - 
 
All the HBS Ag +ve / Anti HCV + were in the age group ≤40 
years 
HBV/HCV Prevalence
7 1 3
89
HBV alone Both HBV and HCV +
HCV alone Both HBV and HCV-ve
Table-XVI 
 
Sex related prevalence of HBV / HCV 
 
Sex N
o.
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Male 75 7 3 1 9.3% 4% 1.3% 
Female 25 1 1 0 4% 4% - 
 
 Out of the 8 individuals who were tested positive for 
Hepatitis B surface antigen 7 were males and one was a 
female.  Percentage being 9.3% and 4% respectively. 
 Out of the 4 individuals who were tested positive for anti 
HCV, 3 were males and one was a female.  Prevalence being 
4% in men and women.  The only individual in whom both 
HBsAg and anti HCV were tested positive was a male.  
Percentage being 1.3%  of total male population. 
Table-XVII 
Mode of transmission/acquisition for HBV / HCV 
Mo
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Heterosexual 93 6 1 - 6.5% 1.1% - 
Injection drug user 5 2 3 1 40% 60% 20% 
Blood / Blood 
related products 1 - - - - - - 
Not known 1 - - - - - - 
 
1. Thus out of 8 cases of HBsAg+ve persons, 6 acquired 
the infection through heterosexual route and the 
remaining two through injection drug use.  That means 
75%  of cases through hetero sexual route and 25% 
through injection drug use. 
2. But only 6.5 % among heterosexually exposed group 
turned out to be positive for HBsAg.  Meanwhile 40% of 
injection drug uses were tested positive for HBsAg.   
 p value > 0.05*            
3. Injection drug users accounted for 3 out of 4 anti HCV 
positive cases thus comprising 75 % and one case , 25% 
acquired the infection through heterosexual route. 
4.     Thus 60% of injection drug users and 1.1% heterosexual 
group tested positive for anti HCV. 
 p value < 0.001* 
 
Table-XVIII 
HBV / HCV Distribution based on CD4 count 
CD4 count 
To
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>500 3 - - - - - - 
200-499 33 1 - - 3% - - 
50-199 52 6 2 - 11.5% 3.84% - 
<50 12 1 2 1 8.3% 16.7% 8.3% 
 
) Out of the 8 persons with HBsAg positivity, 7 had CD4 
counts below 200 and one had CD4 count more than 
200.  The only one person with HBsAg positivity with 
CD4 count below 50 had associated HCV co-infection.   
p value > 0.05*. 
 
 ) Out of the 4 persons with anti HCV positivity all the four 
were having CD4 counts below 200 and two among 
them having CD4 counts below 50.  It has to be noted 
that one person with CD4 count below 50 who was 
tested positive for anti HCV had HBsAg positivity also. 
p value >0.05* 
Table-XIX 
HBV / HCV Distribution based on WHO stage 
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I 17 1 - - 5.9% - - 
II 33 3 - - 9.1% - - 
III 41 3 1 - 7.3% 2.4% - 
IV 9 1 3 1 11.1% 33.3% 14.3% 
 
) Thus out of the 8 HBsAg+ve patients, 3 each were in 
clinical stage II and III and one each in clinical  
stage I & IV. 
p value >0.05* 
) Of the 4 anti HCV+ve individuals, there were three in 
clinical Stage IV and the remaining one patient in  
Stage III. 
p value <0.001* 
) The only one patient with HBV/HCV/HIV co-infection 
was in Stage IV.  
p value <0.01* 
Table-XX 
Elevated transaminase level in the study population 
Serology status Total Normal SGOT/SGPT 
High 
SGOT/SGPT 
% of High 
SGOT/SGPT 
HBsAg+/anti HCV- 7 4 3 42.9% 
HBsAg-/anti HCV+ 3 1 2 66.7% 
HBsAg+/anti HCV+ 1 - 1 100% 
HBsAg-/anti HCV- 89 78 11 12.4% 
 
 When only HBV co-infection was associated with HIV 
there was an increased level of transaminases in three 
out of seven cases i.e.42.9%       p value <0.01* 
 When only HCV co-infection was associated with HIV 
infection there was an increased level of transaminases 
in 2 out of 3 cases i.e. 66.7%.      p value <0.01* 
 When both HBV and HCV co-infections were there with 
HIV infection, there was an increased level of 
transaminases in all the cases / case i.e. 1 out of 1 
(100%).          p value <0.01* 
 Multivariate logistic regression was performed to know 
the effect of age, sex and alcohol on liver enzymes in co-
infected patients but was found to be statistically 
insignificant. 
Table-XXI 
 
Alkaline Phosphatase levels with WHO stage. 
 
WHO Stage Normal value High Value 
I 14 3 
II 21 12 
III 19 22 
IV 1 8 
 
 
 High Alkaline Phosphatase levels were seen with worse 
WHO clinical stages.  Out of 9 persons in WHO clinical stages 
IV, there were 8 persons with increased alkaline phosphatase 
levels while in clinical Stage III, 22 out of 41, in II, 12 out of 
33 and in Stage I, 3 out of 17 had higher values. 
p value < 0.01* 
 
Table-XXII 
Alkaline phosphatase levels with CD4 count 
CD4 count Normal High value 
> 500 3 - 
200-499 26 7 
50-199 24 28 
<50 2 10 
 With decreasing CD4 count higher number of increased 
alkaline phosphatase levels were observed.  p value < 0.001* 
Table-XXIII 
G.G.T. values with clinical stages of HIV 
WHO Stage Normal range High values 
I 16 1 
II 32 1 
III 33 8 
IV 6 3 
p value < 0.05* 
Table-XXIV 
G.G.T. values with CD4 counts 
CD4 counts Normal range High values 
>500 3 - 
200-499 33 - 
50-199 42 10 
<50 9 3 
p value < 0.5* 
In most of the patients with increased alkaline Phosphatase 
level there was a high proportion of raised GGT levels.  It  
co-related with worse stages of HIV infection and lower CD4 
counts which were significant statistically. 
Serum Bilirubin :   Serum Bilirubin was within normal limits 
for all the patients. 
 
Ultrasound Abdomen :  None of the patients co-infected with 
HBV had abnormality in their ultrasonogram.  Only one 
among the four HCV co-infected patients had increased liver 
echoes which was not statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
*p values : Level of Significance 
>0.05 – statistically not significant at 5% level  
<0.05 – statistically significant at 1-5% level 
<0.01 – statistically significat at 1% and below. 
 
DISCUSSION 
 
1. AGE AND SEX DISTRIBUTION 
 
 Most of the patients in the study were in their twenties 
and thirties which is the economically productive age group. 
The mean age of the study group was 34.79 and Male: Female 
ratio was 3:1.  It is estimated that in India HIV / AIDS cases 
reported consist of approximately 73% men and 27% women  
with  89% of reported cases in the age group of 15-44 years 
(26).  
2. PREVALENCE 
Of the 100 HIV infected patients, 8 were found to have 
positivity for Hepatitis B surface antigen (8%), 4 were found to 
have positivity for anti HCV (4%) and one was found to have 
positivity for both HBS Ag and anti HCV. Thus a total of 8% in 
this study population have co-infection with Hepatitis B, 4% 
with Hepatitis C Virus and 1% has co-infection with both 
Hepatitis B and Hepatitis C virus.  
 
The prevalence of Hepatitis co-infection with HIV varies 
widely across different studies.  
 TABLE-XXV 
Prevalence of HBV/HCV co-infection in HIV patients - 
studies in India. 
 
Sl.No. 
Study By HIV + 
HBV 
HIV + 
HCV 
1 Padmapriyadarsini etal: 
(7) 
(Chennai) 6.4% 2.1% 
2 Rogers etal (5, 7) 4% 3% 
3 Ramanamma etal (21) 14.3 - 
4 Tankhivale SS etal 
(11) 
(Maharashtra) 30.4% 7.27 
5 Shazia M Ahson etal 
(3) 
(Mumbai) 3.5% 8% 
6 Dhan Vijay etal (28) 28%  
7 K.Agarwal etal (6) (Delhi) 13%  
 
 
TABLE-XXVI   
HBV / HCV co-infection - Foreign Studies 
Sl.No. Study By HBV% HCV% 
1 Petrus Uchenna Inyama 
(8) 
(Nigeria) - 5.7% 
2 J.Ockenga etal (17, 29) 9% 23% 
3 Saillour F etal (22) 6.9% 42.5% 
4 Dimitrakopoulos (23) 67.4% 13.8% 
5 Treilinger etal (24) 3.1% 54.7% 
6 C.Larsen etal (9) 7% 24.3% 
 
 
Sl.No. Study By HBV% HCV% 
1 Present Study 8% 4% 
 
A cluster survey conducted in randomly selected 
districts of Tamilnadu showed that the overall community 
prevalence of Hepatitis B as 5.3% (27). It is estimated that in 
India prevalence of Hepatitis B virus infection is 5% and 
Hepatitis C virus infection is 2% (30) (19). There is another report 
available which puts the sero prevalence in India for Hepatitis 
B as 3% (HBS Ag.) and 1-1.5% for anti HCV (Hepatitis.C) (15). 
The prevalence  in this study is higher than these statistics, 
the reason being the high risk behaviour in the study group. 
The slightly higher prevalence rates in this study when 
compared to two other studies conducted in Chennai (7,5) may 
be due to variation in the institution where the studies were 
conducted or distribution of risk factors among the selected 
study group. The high variation in prevalence of co-infection 
of HBV or HCV in HIV reported from different parts of world 
and India may again be due to distribution of risk factors, 
geographic location, etc., of the study population. 
 MODE OF TRANSMISSION / ACQUISITION 
 
Out of 8 HBS Ag positive persons there were 6 persons 
who acquired the infection through hetero sexual mode. The 
rest of them, 2 in number, acquired the infection through 
injection drug use. But only 6.5% among the hetero sexually 
exposed group turned out to be positive for HBS Ag, but 40% 
of injection drug users tested positive for HIV. But these were 
found to be statistically insignificant.  
 
While, in the case of Anti HCV positivity, of the 4 anti 
HCV positive patients there were 3 persons who got the 
infection through injection drug use and one through 
probably hetero sexual mode i.e., 75% by injection drug use 
and 25% by heterosexual route. Thus 60% of injection drug 
users and 1.1% of heterosexually exposed group had evidence 
of Hepatitis C co-infection. This observation showed statistical 
significance.  
 TABLE-XXVII 
Some of the studies conducted in India and other 
countries on injection drug users. 
  
Sl.
No. Study By 
Co-infected 
HBV 
Co-infected 
HCV 
1 Baveja etal (14) 2003 39.5% 36.45% 
2 Sunil Solomen (16) etal 12% 85.2% 
3 Decarvalho etal (33) 75% 75% 
4 Saha mk etal (31) 100% 92% 
5 Perdas etal (32) 20%  
 
Thus all these studies prove a higher incidence of HIV, 
HBV, HCV Co-infection in this particularly high risk group of 
injection drug users.  
 
EFFECT OF CO-INFECTIONS ON IMMUNE STATUS 
Out of the 8 HBS Ag positive people 7 had their CD4 
counts below 200, of them one with CD4 count below 50. One 
had CD4 count in between 200 and 499. These observations 
were not statistically significant. But all the HCV infected 
persons had CD 4 counts below 200 / µL. Out of them two 
had CD 4 counts below 50. Whether HCV accelerates 
progression of HIV-I disease is unknown. But many recent 
studies have reported that HCV infection might accelerate 
progression of HIV-I infection. But it is not sure whether HCV 
co-infection worsens the immunological dysfunction already 
present in the host. 
The majority of studies conducted so far on the effect of 
HBV co-infection on the course of HIV progression have given 
conflicting results. Thus no definitive proof for role of HBV on 
HIV disease progression has been reported so far (1). The 
finding regarding HBV co-infection on HIV in this study was 
also statistically insignificant.  
Of the 8 persons infected with hepatitis B in the present 
study, there were 3 persons each in clinical stage II and III 
and one person each in WHO clinical stages I and IV. These 
observations were shown insignificant by statistical analysis.  
But of the 4 persons found to be co-infected with 
Hepatitis C virus, 3 persons were in clinical stage IV and the 
remaining one patient in Stage III. So in this study all the 
HCV co-infected patients had poorer clinical stages and lower 
CD4 counts suggestive of poor immune status. The 
correlation between HCV co-infection and poor WHO clinical 
stage was statistically significant (P<0.0001). 
The only patient with HBV, HCV co-infection; with HIV 
was also in clinical stage IV and was also having CD4 count 
below 50. Though the association between HBV Co-infection 
and lower CD4 count was found to be statistically 
insignificant,  the association with worse WHO clinical stage 
was statistically significant  
 
IMPACT OF CO-INFECTION ON LIVER FUNCTION 
The impact of co-infection on liver function was also 
analysed. This was done by looking at elevated transminase 
levels (ALT or AST). It was shown in the study that 42.9% of 
cases with Hepatitis B co-infection alone had a rise in 
transaminase levels. In those with evidence of Hepatitis C co-
infection alone had a rise in transminase level in 66.7% of 
cases and in the case of Hepatitis B and C co-infection had a 
rise in 100% case (one out of one). These associations were 
proved significant statistically. Logistic regression was used to 
analyse the impact of the other obvious, hepatotoxic agent, 
alcohol on transminases in patients with co-infection and was 
found insignificant.  
 
Hepatitis B virus is a non-cytopathic virus that causes 
liver damage mainly through immune mediated mechanisms. 
But the risk of HBV associated end stage liver disease seems 
to be increased in the setting of HIV co-infection. This is 
because the presence of HIV infection increases the risk of 
chronicity of HBV infection, as well, reduces the rate of 
spontaneous HBS Ag seroconversion. Despite the proposed 
milder hepatic necro inflamation in HBV co-infected HIV 
patients, in agreement with the postulated immune mediated 
pathogenicity, there are reports of enhanced HBV replication 
levels leading on to progression of more severe liver disease (1).  
 
HIV I infection appears to speed the rate of progression 
of chronic hepatitis C to end stage liver disease to as little as 
10 years after exposure. However, this accelerated progression 
has not been observed in all studies. Data from a meta 
analysis indicate that the average risk for progressive liver 
disease is 2.9 times higher among HCV / HIV - I co-infected 
persons than among persons infected only with HCV (2) (25). 
 
A study from Mumbai (3) showed higher serum 
transaminase levels in most of the HCV co-infected persons 
but there was no evidence of elevated transminases in 
Hepatitis B co-infection group. But a study from Chennai (7) 
recorded higher transaminase values for those co-infected 
with HBV when compared to non HBV group of HIV +ve 
patients.  
 
HIV & ALKALINE PHOSPHOTASE LEVELS 
The effect of HIV infection on the level of alkaline 
phosphatase was studied in the population. In the study 
group a higher proportion of patients with elevated alkaline 
phosphatase levels were seen in worse WHO clinical stages as 
well as in patients with low CD4 counts. These findings were 
significant on statistical analysis also. HIV infection is known 
to cause a rise in alkaline phosphatase levels (7). This has 
been linked to the progression of disease as well. Those 
patients with increase alkaline phosphatase level had either 
high normal values of GGT or abnormally high GGT values 
which also showed correlation with worse stages of HIV 
infection, which were significant statistically also.  
 
This study has its share of limitations as well. This data 
may have underestimated the true prevalence of HBV co-
infection. Atypical serum HBV markers are a problem among 
some HIV infected individuals as in some of them isolated 
anti-hepatitis B core antigen is recognised, particularly among 
patients with severe immune deficiency (1, 13). 
 
The underestimation may have also occurred in the case 
of Hepatitis C co-infection as well because at least 4% of HIV - 
HCV co-infected patients have no detectable anti HCV 
antibodies in the presence of HIV viremia (16, 12). Also HCV 
RNA could not be tested which is considered as the gold 
standard in the diagnosis of Hepatitic C infection. But the test 
performed in this study has a sensitivity of 99% and 
specificity of 97%. 
CONCLUSIONS 
 
The prevalence of HBV co-infection was found to be 8% 
in HIV patients in this study.  
 
The prevalence of HCV co-infection in HIV patients in 
the study population was 4%. 
 
The prevalence of HBV, HCV co-infection in the study 
population was 1%. 
 
The majority of Hepatitis B co-infections were acquired 
through heterosexual route. But 40% of injection drug users 
were co-infected with HBV. But these observations are not 
statistically significant.  
 
Injection drug use accounted for 75% of cases of 
Hepatitis C infection and 60% of injection drug users had 
Hepatitis C co-infection, making injection drug use the main 
mode of transmission for this co-infection. This observation is 
significant statistically also.  
 
Both Hepatitis B and Hepatitis C co-infection caused 
statistically significant elevation of transaminase levels thus 
predicting on going liver damage. While Hepatitis B co-
infection did not produce statistically significant impact on 
HIV disease progression, hepatitis C co-infection caused 
statistically significant impact on HIV disease progression 
with lower CD 4 counts and worse WHO clinical stages.  
 
There was significant association between  HIV disease 
progression and level of alkaline phosphatase. Serum GGT 
also showed a similar trend with worse WHO clinical stages 
and lower CD4 counts. 
 
The prevalence of Hepatitis B and Hepatitis C co-
infection is fairly high in HIV infected population of 
Government General Hospital and Madras Medical College 
supporting the use of more careful screening for these viruses 
in this institution. Particularly in injection drug users 
screening for Hepatitis B and C should be undertaken. 
SUMMARY 
 
Hepatitis B virus, Hepatitis C virus and Human immuno 
deficiency virus have in the recent years posed significant 
challenges to the health care system.  
 
The aim of this study was to know the prevalence and 
impact of Hepatitis B virus and Hepatitis C virus co-infection 
in HIV patients of Madras Medical College and Government 
General Hospital.  
 
Altogether one hundred HIV positive patients in 
Government General Hospital and Madras Medical College 
were selected by random sampling and were screened for 
Hepatitis B surface antigen and anti HCV. Liver function tests 
and ultra sonography of abdomen were done. Statistical 
analysis was done and p values were estimated wherever 
necessary.  
 
Results showed that prevalence of Hepatitis B co-
infection as 8%, Hepatitis C co-infection as 4% and Hepatitis 
B and Hepatitis C co-infection together as 1% in HIV 
population. There was significant elevation of liver enzymes 
with co-infection.  
 
On the basis of higher prevalence rates for Hepatitis B and 
Hepatitis C co-infection routine screening for these viruses is 
necessary in HIV positive population. 
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PROFORMA 
 
1. Name 
2. Age 
3. Sex 
4. Occupation 
5. Education 
6. Marital Status 
7. HIV diagnosed on 
8. Mode of Acquisition 
 a) Sexual Æ Hetero/Homosexual 
   Æ Contact with commercial sex worker 
   Æ Multiple sex partners 
 b) Injection drug user. 
 c) Blood transfusion 
 d) Iatrogenic 
 e) Unknown 
9. Alcoholic intake 
10. HIV status of partner / Spouse 
11. CD4 count 
12. WHO clinical stage 
 - Weight loss - a) Yes / No 
       - b) Weight loss, if there - >10% of <10% 
 - Activity  - Limited / Normal  
   - No. of days inactive the previous month 
 - Persistent generalised lymphadenopathy +/- 
 - Acute HIV syndrome - Yes / No 
 - Oral candidiasis - Yes / No 
 - AIDS  defining illness 
 - Pulmonary tuberculosis 
13. Liver function test 
 - Serum Bilirubin 
 - AST / SGOT 
 - ALT / SGPT 
 - GGT 
 - S.Alkaline phosphatase 
 
14. Ultrasonogram - Abdomen 
 - Liver - Size / echoes 
 - Spleen / Splenic vein 
 - Portal vein 
 - Ascites  
 - Venous collalevals. 
 
LFT 
Sl.No. Number IP/OP Age Sex Education 
Marital 
Status 
HIV 
Status 
of 
Spouse 
Mode of 
Transmission 
Alcohol 
intake 
CD4 
Count 
WHO 
Stage 
HBs 
Ag 
Anti 
HCV SBb SGOT SGPT GGT ALP 
USG 
 
1 844/06 37 M U.P.School Married -ve Heterosexual  Yes 254 II -ve -ve 1.0 24 26 32 78 N 
2 753329 35 M U.P.School Married +ve Heterosexual No 109 III -ve -ve 0.8 24 22 25 72 N 
3 113228 40 M U.P.School Married        N K Heterosexual Yes 45 III -ve -ve 0.8 38 31 40 136 Fatty Liver 
4 141280 33 M SSLC Married        N K Heterosexual No 148 III -ve -ve 0.9 32 32 30 98 N 
5 56945 54 M L.P. School Married -ve Heterosexual No 94 III -ve -ve 1.1 32 30 28 84 N 
6 122329 26 M SSLC Not Married - Heterosexual No 340 I -ve -ve 0.6 28 26 28 58 N 
7 143790 48 F U.P.School Married +ve Heterosexual No 178 IV -ve -ve 1 30 41 20 84 N 
8 165865 40 M Hr.Secondary Married +ve Heterosexual Yes 86 III +ve -ve 1.2 59 49 48 98 N 
9 103411 28 M SSLC Not Married - Heterosexual No 235 III -ve -ve 1.2 32 30 30 68 N 
10 17973 35 M SSLC Married +ve Heterosexual Yes 40 III -ve -ve 0.9 58 28 52 186 N 
11 38774 40 M High School Married N K Heterosexual Yes 45 IV -ve -ve 0.8 58 28 39 180 N 
12 120146 40 M High School Married +ve Heterosexual No 230 II -ve -ve 0.8 34 32 28 70 N 
13 40631 31 M U.P.School Married +ve Heterosexual No 58 III -ve -ve 0.6 32 30 36 132 N 
14 77268 24 M SSLC Not Married - IVDU No 39 IV +ve +ve 1.2 85 80 52 163 N 
15 140179 32 M SSLC Married -ve Heterosexual Yes 146 III -ve -ve 1.1 24 26 38 138 N 
16 122743 26 M Diploma Married +ve Heterosexual No 181 II +ve -ve 0.9 25 25 42 176 N 
17 158548 38 M SSLC Married -ve BT Yes 206 II -ve -ve 0.5 108 51 42 356 Fatty Liver 
18 101645 39 M SSLC Not Married - Heterosexual Yes 231 I -ve -ve 0.6 21 28 31 65 Fatty Liver 
19 35802 26 M U.P.School Not Married - Heterosexual No 49 III -ve -ve 0.9 20 18 34 165 N 
20 121318 45 M L.P. School Married -ve Heterosexual Yes 69 IV -ve -ve 1.2 58 28 48 188 Fatty Liver 
21 96804 40 F L.P. School Married -ve Heterosexual No 11 IV -ve -ve 0.5 23 16 28 168 N 
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Status 
HIV 
Status 
of 
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intake 
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Ag 
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HCV SBb SGOT SGPT GGT ALP 
USG 
 
22 131631 35 F High School Married +ve Heterosexual NO 430 II -ve -ve 0.7 28 22 21 97 N 
23 102404 32 M Diploma Not Married - Heterosexual NO 642 I -ve -ve 1 40 58 30 122 N 
24 37518 38 F High School Married +ve Heterosexual NO 35 III -ve -ve 0.8 25 19 20 105 N 
25 234197 34 M High School Married -ve Heterosexual NO 8 IV -ve -ve 0.8 32 30 40 220 N 
26 1432/06 29 M SSLC Not Married - Heterosexual YES 160 III -ve -ve 0.6 26 30 24 104 N 
27 110125 35 M Diploma Married -ve Heterosexual NO 136 II -ve -ve 0.7 24 16 28 106 N 
28 154574 48 F L.P.School Married -ve Not known NO 72 II -ve -ve 0.9 29 30 22 98 Fatty liver 
29 107645 40 F L.P.School Married +ve Heterosexual NO 53 III -ve -ve 0.8 33 44 28 151 N 
30 113812 33 M No Not Married - IVDU YES 178 III -ve +ve 1 38 36 44 110 N 
31 124935 29 F U.P.School Married +ve Heterosexual NO 158 I +ve -ve 0.6 87 42 71 153 N 
32 141280 33 M SSLC Married -ve Heterosexual NO 256 II -ve -ve 0.9 29 33 24 110 N 
33 43720 35 M SSLC Married +ve Heterosexual YES 118 III -ve -ve 0.7 29 33 28 156 N 
34 131601 27 M U.P.School Married N K Heterosexual YES 122 III -ve -ve 0.9 46 38 26 97 N 
35 169198 30 M High School Married -ve Heterosexual YES 96 III -ve -ve 0.8 33 36 30 126 N 
36 136689 35 F High School Married +ve Heterosexual NO 28 IV -ve +ve 1.7 180 148 68 300 N 
37 160139 28 F L.P.School Married +ve Heterosexual NO 260 I -ve -ve 0.8 48 37 24 120 N 
38 101686 36 M U.P.School Married -ve Heterosexual YES 120 III -ve -ve 1.1 56 49 34 89 N 
39 97676 30 M High School Not Married - Heterosexual YES 68 III -ve -ve 1.2 59 49 30 91 N 
40 1603/05 29 M Hr.Secondary No - Heterosexual NO 182 II +ve -ve 1.1 38 44 36 133 N 
41 155710 38 F L.P.School Yes +ve Heterosexual NO 280 I -ve -ve 0.8 24 34 29 168 N 
42 146103 36 F High School Married +ve Heterosexual NO 380 I -ve -ve 0.6 22 28 26 76 N 
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43 133817 32 M High School Married -ve Heterosexual YES 82 III -ve -ve 1.1 29 34 28 183 Fatty liver 
44 802283 30 M U.P. School Married -ve Heterosexual YES 120 III -ve -ve 1 49 40 38 150 N 
45 68721 35 F High School Married +ve Heterosexual NO 48 III -ve -ve 1 32 27 20 81 N 
46 136102 35 M High School Married -ve Heterosexual NO 110 II -ve -ve 0.8 27 26 26 199 N 
47 209070 28 M SSLC Not Married - Heterosexual NO 192 II -ve -ve 0.8 46 37 38 261 N 
48 100536 35 M High School Married -ve Heterosexual YES 220 II -ve -ve 0.9 35 26 34 136 N 
49 815145 30 M L.P. School Married -ve Heterosexual YES 192 II -ve -ve 0.8 34 24 38 140 N 
50 1250106 30 F L.P. School Married +ve Heterosexual NO 220 I -ve -ve 0.8 29 23 20 67 N 
51 2557/05 44 M U.P. School Married +ve Heterosexual YES 220 II -ve -ve 0.9 26 18 30 126 N 
52 19455 34 M Diploma Married -ve Heterosexual NO 140 III -ve -ve 0.9 33 28 38 150 N 
53 33274 46 M U.P. School Married -ve Heterosexual NO 230 II -ve -ve 0.8 34 38 40 184 N 
54 176059 27 F High School Married +ve Heterosexual NO 320 I -ve -ve 0.8 35 27 20 126 N 
55 188505 35 M High School Married +ve Heterosexual YES 110 III -ve -ve 0.9 28 21 32 95 N 
56 179727 29 M U.P. School Not Married - Heterosexual NO 180 II -ve -ve 0.9 32 26 24 98 N 
57 57845 24 F L.P. School Married +ve Heterosexual NO 360 I -ve -ve 0.8 21 20 18 87 N 
58 113830 33 M High School Married +ve Heterosexual YES 122 III +ve -ve 0.8 29 28 26 92 N 
59 33643 28 M High School Not Married - Heterosexual NO 210 II -ve -ve 1 26 29 38 166 N 
60 213410 32 M U.P. School Married -ve Heterosexual NO 140 III -ve -ve 1.1 30 32 38 180 N 
61 115841 23 F High School Married +ve Heterosexual NO 268 I -ve -ve 1 18 16 16 33 N 
62 148149 34 M U.P. School Married +ve Heterosexual NO 88 III +ve -ve 1.2 48 54 51 166 N 
63 48617 26 M U.P. School Not Married - Heterosexual NO 116 III -ve -ve 0.7 29 26 43 180 N 
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64 215043 30 M B.A. Not Married - Heterosexual NO 176 II -ve -ve 0.6 28 20 29 114 N 
65 99602 38 F Not educated Married +ve Heterosexual NO 320 I -ve -ve 0.9 28 23 26 131 N 
66 31541 35 F U.P. School Married +ve Heterosexual NO 180 III -ve -ve 0.7 23 20 28 161 N 
67 35921 42 M High School Married +ve Heterosexual YES 226 II -ve -ve 0.9 28 26 30 112 N 
68 35929 36 M High School Married -ve Heterosexual YES 520 I -ve -ve 0.6 24 26 26 113 N 
69 701104 38 M B.A. Married -ve Heterosexual NO 163 II -ve -ve 0.8 23 25 22 75 N 
70 1392156 45 F L.P. School Married +ve Heterosexual NO 92 III -ve -ve 0.6 26 22 20 80 N 
71 1392182 25 F U.P. School Married +ve Heterosexual NO 420 I -ve -ve 0.6 21 29 20 91 N 
72 138968 40 M U.P. School Married NA IVDU YES 260 II +ve -ve 0.8 23 42 38 107 N 
73 38474 36 M B.A. Married -ve Heterosexual NO 160 III -ve -ve 1.4 77 81 52 114 N 
74 430011 32 M Hr.Secondary Married -ve Heterosexual YES 210 II -ve -ve 1.1 54 26 30 80 N 
75 40531 31 M High School Married -ve Heterosexual NO 210 II -ve -ve 1 16 18 24 115 N 
76 182549 35 M SSLC Married -ve Heterosexual YES 128 II -ve -ve 1.1 44 32 30 119 N 
77 147512 39 M B.A. Married -ve IVDU NO 96 IV -ve +ve 0.9 55 59 61 176 N 
78 135052 41 M L.P. School Married +ve Heterosexual YES 204 III -ve -ve 0.7 21 28 20 78 N 
79 138553 40 M B.A. Married - ve Heterosexual NO 648 I -ve -ve 0.7 30 25 22 79 N 
80 203499 50 M L.P. School Married - ve Heterosexual NO 214 II -ve -ve 0.6 18 16 20 72 N 
81 826733 30 M High School Not Married - ve Heterosexual YES 62 III -ve -ve 0.8 38 23 56 289 N 
82 144517 44 M b.a. Married - ve Heterosexual YES 186 II -ve -ve 0.8 24 32 30 108 N 
83 97314 43 F L.P.. School Married + ve Heterosexual NO 220 III -ve -ve 1 30 28 22 88 N 
84 56656 38 F High School Married + ve Heterosexual NO 316 I -ve -ve 1.1 23 20 22 114 N 
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85 106410 33 M Hr.Secondary Married - ve Heterosexual NO 88 III -ve -ve 0.8 20 20 56 158 N 
86 126420 36 M High School Married + ve Heterosexual YES 114 III -ve -ve 0.9 29 25 52 138 N 
87 968103 32 M U.P. School Not Married - Heterosexual YES 312 II -ve -ve 1 30 28 28 90 N 
88 286105 50 M U.P. School Married - ve Heterosexual NO 172 II -ve -ve 0.9 19 22 58 209 N 
89 954105 33 M B.A. Married - ve Heterosexual YES 220 II -ve -ve 1.1 35 37 41 168 N 
90 130046 38 M High School Married - ve Heterosexual YES 160 II -ve -ve 1 43 40 32 98 N 
91 122327 30 F U.P. School Married + ve Heterosexual NO 46 III -ve -ve 0.9 26 27 31 189 N 
92 98184 47 M High School Married - ve Heterosexual YES 118 II -ve -ve 0.8 24 28 26 101 Fatty Liver 
93 70618 28 F High School Married + ve Heterosexual NO 80 III -ve -ve 1.1 36 33 52 275 N 
94 52810 38 M Diploma Married + ve Heterosexual NO 110 II -ve -ve 0.8 17 19 38 133 N 
95 127188 26 M High School Not Married - IVDU NO 260 II -ve -ve 1.1 22 29 28 76 N 
96 202105 35 M B.A. Married + ve Heterosexual NO 68 III -ve -ve 0.9 30 32 62 232 N 
97 173105 32 M L.P. School Married + ve Heterosexual YES 130 III -ve -ve 1.3 41 52 42 141 N 
98 1175/05 36 M Hr.Secondary Married + ve Heterosexual NO 38 IV -ve -ve 0.9 36 35 42 172 N 
99 120414 25 F U.P. School Married + ve Heterosexual NO 342 I -ve -ve 0.9 20 21 24 84 N 
100 171402 35 M Hr.Secondary Married + ve Heterosexual NO 132 III -ve -ve 0.9 22 28 42 143 N 
NK = Not Known 
